FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Heritage Pharmaceuticals Felodipine Extended Release Tablets Recall

Felodipine Extended Release Tablets, USP 10 mg,100-count bottle, Rx only, Distributed b…

Heritage Pharmaceuticals Inc · East Brunswick, NJ

Risk level
Class III
Reported by FDA
Dec 2, 2020
Recall ID
D-0108-2021
Check your lot numberHow we source this data

Summary

Heritage Pharmaceuticals recalled Felodipine Extended Release Tablets starting Oct 23, 2020. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0108-2021 on Dec 2, 2020. Reason: Failed impurities/ degradation specifications: Out of specification impurity results were observed during routine testing of stability samples for the impurity Felodipine Related compound A. Status: Terminated.

Why it was recalled

Failed impurities/ degradation specifications: Out of specification impurity results were observed during routine testing of stability samples for the impurity Felodipine Related compound A

Product description

Felodipine Extended Release Tablets, USP 10 mg,100-count bottle, Rx only, Distributed by: Heritage Pharmaceuticals Inc. East Brunswick, NJ 08816 Made in India, NDC 23155-050-01

Lot numbers, UPCs & expiration codes

Lot #: 18029979, Exp 1/2021

Where it was sold

USA Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0108-2021
Classification
Class III
Status
Terminated
Recall initiated
Oct 23, 2020
FDA report date
Dec 2, 2020
Quantity
7176 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Heritage Pharmaceuticals Inc

Original FDA data

Every field from FDA enforcement report D-0108-2021, exactly as published.

Show all FDA fields
City
East Brunswick
State
NJ
Status
Terminated
Country
United States
Event ID
86659
Address
1 Tower Center Blvd Ste 1700
Code information
Lot #: 18029979, Exp 1/2021
Postal code
08816-1145
Report date
Dec 2, 2020
Product type
Drugs
Recall number
D-0108-2021
Classification
Class III
Recalling firm
Heritage Pharmaceuticals Inc
Product quantity
7176 bottles
Termination date
Jan 28, 2022
Reason for recall
Failed impurities/ degradation specifications: Out of specification impurity results were observed during routine testing of stability samples for the impurity Felodipine Related compound A
Voluntary / mandated
Voluntary: Firm initiated
Product description
Felodipine Extended Release Tablets, USP 10 mg,100-count bottle, Rx only, Distributed by: Heritage Pharmaceuticals Inc. East Brunswick, NJ 08816 Made in India, NDC 23155-050-01
Distribution pattern
USA Nationwide
Recall initiation date
Oct 23, 2020
Initial firm notification
Letter
Center classification date
Nov 25, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0108-2021, published Dec 2, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls